We read with great interest the elegant but provocative study of Fujii et al 1 assessing mechanisms of drug-eluting stent (DES) failure in patients treated for in-stent restenosis (ISR). Focal recurrence after DES treatment occurred in 25% of patients. Eleven patients with ISR recurrence showed evidence of severe stent underexpansion on intravascular ultrasound (minimal stent area Ͻ5 mm 2 in 9 lesions, Ͻ4 mm 2 in 7 lesions, and Ͻ3 mm 2 in 4 lesions). Of interest, these findings were demonstrated despite the routine use of high inflation pressures (Ն14 atm by protocol). Because the study has major potential clinical implications, further details and some methodological considerations would be appreciated to better delineate the pattern of ISR in these patients.
high shear stress could contribute to the genesis of restenosis, whereas in the latter, minimal stent area per se will emerge as the main player accounting for lumen narrowing.
Finally, from a pragmatic standpoint, it would be important to provide further therapeutic alternatives when significant DES underexpansion is detected by intravascular ultrasound after the procedure, because the systematic use of very high pressures (18Ϯ4 atm in this study) does not appear to prevent the occurrence of this phenomenon.
We fully agree with these investigators that the efficacy of DES in the treatment of patients with ISR is currently not completely established. [2] [3] [4] [5] Therefore, prospective controlled studies are warranted to further define the role of DES in the challenging setting of ISR.
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